179 results about "Liver fat" patented technology

The invention relates to the technical field of grass carp, in particular to a molecular marker associated with body fat traits of grass carp and application. The invention discloses SNPs molecular markers associated with a grass carp FABP3 gene and a body fat character. The SNPs molecular markers are respectively located at the basic group positions of 29945677, 29948389 and 29948502 of a No.19 chromosome of a grass carp reference genome GCF019924925.1. The three SNPs molecular markers are closely associated with body fat traits such as the abdominal fat index, the liver fat content and the muscle fat content of the grass carp. The molecular marker can be applied to molecular-assisted selective breeding of low-fat grass carp strains.

The invention relates to pediococcus pentosaceus with a cholesterol lowering function and application thereof, and belongs to the technical field of microorganisms. The invention discloses pediococcus pentosaceus with a cholesterol lowering function and application of the pediococcus pentosaceus. The pediococcus pentosaceus R5 (GDMCC No.65659) is separated from special fermented food stinky acid in Guizhou. The in-vitro cholesterol removal rate of the pediococcus pentosaceus R5 can reach 59%, and the pediococcus pentosaceus R5 has the characteristics of acid / cholate resistance, no hemolysis and sensitivity to common antibiotics; an in-vivo lipid-lowering experiment is carried out on a hyperlipidemia model mouse, and the result shows that the strain R5 can remarkably improve the in-vivo dyslipidemia state of the mouse, reduce liver fat accumulation and protect the liver at the same time, and can be used for developing lipid-lowering related probiotic functional products. The strain R5 provided by the invention provides a natural and safe probiotic for preventing and / or treating hyperlipemia.

The invention relates to the technical field of medical image recognition, in particular to a fat content analysis method and system based on a liver pathological section image, and the method comprises the following steps: extracting a liver fat vacuole gravity center sequence, recognizing and arranging mutation nodes, removing abnormal vacuoles, analyzing a boundary structure, extracting a closed boundary, and generating a fat content analysis result. According to the method, through selection of the adjacent pixel group of the structure edge in the fat cavitation region and construction of the gravity center sequence, deep characterization of the fat cavitation arrangement characteristics is realized, and stable reference is provided for subsequent structure identification; abnormal change nodes are identified based on an evolution trend of an included angle of adjacent gravity center vectors in the gravity center sequence, arrangement direction mutation points are effectively positioned, impurity interference is screened out, and misjudgment of fat assessment caused by irregular accumulation is avoided; by means of calculation of a gravity center drift curve and a compactness variable coefficient, a form fluctuation area is recognized, abnormal cavitation bubbles are removed, and the consistency and stability of structure extraction are enhanced.

The invention discloses a full-automatic ultrasonic liver fat content detection method and system based on double nakagami. The method comprises the following steps: S1, acquiring a B-mode image of an ultrasonic liver and IQ envelope data of an original RF signal; s2, carrying out image segmentation on the B-mode image through a deep learning segmentation method, and segmenting liver parenchyma and blood vessel regions in the image; s3, performing post-processing on a result after image segmentation to obtain a candidate curved-edge trapezoid ROI region only containing liver parenchyma; s4, inputting IQ envelope signal position area data corresponding to the candidate ROI area into a double-nakagami mixed distribution model, and estimating and optimizing model parameters through an algorithm to obtain the fat content in the specified ROI area; according to the invention, full-automatic quantitative detection of the ultrasonic liver fat content is realized, and a doctor or a user is helped to complete detection of the liver fat content on the premise of not depending on ultrasonic clinical knowledge.

The invention relates to the field of biological medicine, in particular to application of hispidulin in preparation of a lipid de novo synthesis inhibitor or a metabolism-related fatty liver disease treatment or prevention product. The hispidulin disclosed by the invention has a chemical structure as shown in a formula (I). The hispidulin in the invention reverses liver cell lipid droplet excessive infiltration induced by high-dose fructose in a dose-dependent manner; furthermore, the hispidulin dose-dependent ameliorating obesity signs in HFD-induced MAFLD model mice, including liver weight, body weight, blood lipid level, liver fat content, and insulin resistance, without significantly reducing food intake.

The present disclosure relates to a method. The method includes accessing automatically segmented liver data and automatically segmented spleen data from a patient. The automatically segmented liver data is used to determine a liver attenuation and the automatically segmented spleen data is used to determine a spleen attenuation. A liver-to-spleen attenuation ratio is determined from the liver attenuation and the spleen attenuation. A hepatic steatosis determination is made from the liver-to-spleen attenuation ratio

The invention discloses American ginseng polysaccharide XYS1 and a preparation method and application thereof, the American ginseng polysaccharide XYS1 is neutral alpha glucan, the main chain is composed of 1, 4-alpha-Glcp and 1, 6-alpha-Glcp, C6 of every three 1, 4-alpha-D-Glcp is substituted by one terminal Glcp, and the weight-average molecular weight is 5-100 kDa. Crude polysaccharide is extracted from American ginseng and is identified as neutral alpha glucan through compound enzyme extraction, ion column chromatography purification and spectrum identification, and it is proved that the polysaccharide XYS1 can significantly inhibit depression-like behaviors of mice and reverse behavioral changes caused by chronic stress, and can be used for preparing polysaccharide drugs or functional products for treating depression. The polysaccharide XYS1 can also inhibit liver fatty degeneration and liver fibrosis induced by CCl4, has a certain protection effect on liver cells in vivo, relieves the fibrosis degree, and can be used for preparing polysaccharide drugs or functional products for preventing and treating liver fibrosis.

The invention discloses application of Prevotella copri as a children's metabolism-related fatty liver disease (MASLD) biomarker and a therapeutic target, relates to the fields of medical microbiology and metabonomics, and explores biological characteristics of the Prevotella copri and an action mechanism of the Prevotella copri in children's metabolism-related fatty liver disease (MASLD). The invention also analyzes the effect of Prevotella copri and its metabolite 5-aminovaleric acid in the development of children's metabolism-related fatty liver disease (MASLD), and provides a basis for developing a method for treating metabolism-related fatty liver disease (MASLD) based on intestinal microorganisms. According to the present invention, the Prevotella copri is subjected to intragastric administration to the mouse fed with the high fat diet, such that the liver fat change and the intestinal flora disorder aggravating are found; the metabolite 5-amino valeric acid of the Prevotella copri can be used for aggravating the adiposis of the liver cells. Therefore, the Prevotella copri and the metabolite 5-aminovaleric acid of the Prevotella copri can be used as a biomarker and a therapeutic target for diagnosis, treatment, prognosis evaluation or drug screening of the MASLD (Metabolism-related Fatty Liver Disease) of children.

The invention relates to the field of medicines, and particularly discloses application of mogroside V in preparation of a medicine for dispelling the effects of alcohol and protecting the liver, experiments prove that the anti-alcohol effect of the mogroside V is obviously superior to that of a mogroside crude extract, and in one embodiment, the mogroside V can increase protein expression of ethanol dehydrogenase and acetaldehyde dehydrogenase in the liver of a mouse at the same time. In one embodiment, the mogroside V can prolong the drunkenness tolerance time of a mouse and shorten the drunkenness time of the mouse. In another embodiment, the mogroside V can relieve liver inflammation caused by alcohol. In a further embodiment, the mogroside V can greatly relieve liver fat deposition caused by alcohol. Therefore, the mogroside V can be developed into a brand new product for dispelling the effects of alcohol and protecting the liver, and has a huge application prospect.

The invention discloses application of a polypeptide in preparation of medicines, foods or health-care products for treating obesity and complications thereof, and belongs to the technical field of biological medicines. The polypeptides are human GPR15L polypeptides or mouse GPR15L polypeptides and polypeptide conjugates of the human GPR15L polypeptides or the mouse GPR15L polypeptides. The obesity treatment comprises the steps of reducing fat accumulation, promoting fat heat production and decomposition, increasing energy consumption and reducing body weight. Obesity complications include chronic inflammation, fatty liver, steatohepatitis, metabolic diseases, cardiovascular and cerebrovascular diseases, osteoarticular diseases, Alzheimer's disease, depression, tumors and skin diseases. The blood sugar and the body weight are reduced through a brand new action mechanism, so that the obesity and complications thereof are effectively treated.

The invention relates to the technical field of biological medicine, in particular to radix puerariae and sesame coffee for improving non-alcoholic fatty liver and application of the radix puerariae and sesame coffee. The radix puerariae and sesame coffee comprises the following components in parts by weight: 0.5 part of a fructus cannabis polypeptide solution, 0.5 part of radix puerariae polypeptide solution and 9 parts of coffee. After continuous treatment for 7 weeks, according to liver appearance and liver histopathology observation, it is found that the radix puerariae and sesame coffee mixed liquid effectively reduces lipid deposition and liver fat, and the liver fat lesion is improved. Experimental results show that the radix puerariae and hemp coffee has a remarkable lipid-lowering effect, and can effectively reduce liver fat particles, reduce inflammatory injury, improve liver tissue pathological changes and relieve NAFLD mouse liver tissue injury.

The invention discloses a long-acting GGG three-target agonist, and the compound provided by the invention simultaneously achieves nM-level excellent agonist ability on three targets of GLP-l / GIP / GCGR, and can fully excite corresponding target organ tissue cells. The compound provided by the invention can promote insulin secretion and reduce blood sugar; in addition, ingestion can be inhibited, gastric emptying can be delayed, energy consumption can be increased, and finally the weight reduction effect can be observed. The compound provided by the invention can reduce pancreatic beta-cell apoptosis, increase the quantity of pancreatic beta-cells and improve functions of pancreatic cells. The compound disclosed by the invention can also improve blood fat, reduce liver fat accumulation and inhibit liver inflammation development. The compound or the composition can be used for preventing and / or treating metabolic disorder diseases and related complications thereof. The compound or the composition can be used for treating bone diseases related to endocrine diseases, metabolic disorders, nephropathy and the like, such as osteoporosis and osteoarthritis.

The present invention relates to the technical field of microorganisms, in particular to a Lactobacillus acidophilus GOLDGUT-LA100 having functions of lipid lowering, blood glucose lowering and weight loss and application thereof. The Lactobacillus acidophilus GOLDGUT-LA100 provided by the present invention is preserved in China General Microbiological Culture Collection Center, with the preservation number of CGMCC No. 28398. The strain has strong acid resistance, can adapt to the digestive tract environment, and has high bile salt hydrolase activity. At the same time, in animal experiments, the strain significantly reduces blood glucose and serum cholesterol levels, reduces liver fat deposition, reduces adipose tissue inflammation, effectively reduces the weight, and has broad application prospects in the development of products for improving obesity, lowering lipid and lowering blood glucose.

The invention discloses an FAM20B protein and application of an FAM20B protein inhibitor in prevention or treatment of glucolipid metabolism related diseases. Specifically, the invention discloses an application of an FAM20B protein and / or an FAM20B gene in regulation and control of liver glycolipid metabolism. The invention also discloses application of the FAM20B inhibitor in improving, preventing or treating liver glycolipid metabolism disorder or glycolipid metabolism related diseases (such as diabetes, metabolism related fatty liver disease MAFLD, obesity and the like). Experiments show that the FAM20B inhibitor can reduce the liver gluconeogenesis level, relieve impairment of glucose tolerance, relieve hyperglycemia of diabetic patients, reduce the fat content of the whole body and the liver, relieve liver lipid deposition, promote energy consumption, reduce food intake, promote fat burning and reduce liver fat accumulation; the compound can be used for preparing medicines for preventing and treating glucose and lipid metabolism disorder or glucose and lipid metabolism related diseases, and has a wide application prospect in the fields of prevention and treatment of metabolism related diseases.

The invention discloses a pharmaceutical application of a 3-phenylglutaric acid derivative and a pharmaceutical composition. The 3-phenylglutaric acid derivative can be used for preparing an FASN inhibition drug. The 3-phenylglutaric acid derivative micromolecule 84-B10 can inhibit FASN in a targeted manner, is used for inhibiting the activity of the FASN, promoting the degradation of the FASN and relieving weight gain, liver fat accumulation, insulin sensitivity decline and glucose tolerance impairment caused by high calorie intake, and can be used for preparing medicines for preventing and treating metabolism-related fatty liver diseases.

The invention relates to the technical field of biological medicine, in particular to application of cyclic dipeptide to improvement or treatment of dyslipidemia related diseases. According to the present invention, the research results show that the cyclo (glycerol-casein) dipeptide has good safety and cholesterol lowering activity, and can reduce mouse serum total cholesterol, low density lipoprotein cholesterol, increase serum high density lipoprotein cholesterol, reduce the content of liver total cholesterol, reduce liver fat accumulation, and slow down the weight increase of mice. The cyclic (glycerol-casein) dipeptide can realize the effect of lowering cholesterol by regulating intestinal flora. The cyclic (glycerol-tyrosine) dipeptide is derived from probiotics, food and medicines, belongs to food-borne cyclic dipeptide, and is high in safety and small in toxic and side effects. The cyclo (glycerol-casein) dipeptide is expected to be developed into a class of innovative medicines and health-care foods with the effect of reducing cholesterol, and has a very good application prospect. The invention also provides the cyclic (sweet-tyrosine) dipeptide and a health food and a pharmaceutical composition containing the cyclic (sweet-tyrosine) dipeptide.

The invention belongs to the technical field of functional microorganisms, and provides pediococcus acidilactici MR21 and application thereof. The pediococcus acidilactici MR21 provided by the invention is preserved in the China General Microbiological Culture Collection Center (CGMCC) on December 3, 2024, and the preservation number is CGMCC NO. 32896. The pediococcus acidilactici MR21 disclosed by the invention has efficient in-vitro cholesterol removal capacity, excellent safety and remarkable probiotic characteristics, and has the effects of restoring liver functions, reducing liver fat accumulation and regulating expression of fat and cholesterol metabolism related genes by remarkably reducing the content of serum total cholesterol and low-density lipoprotein cholesterol. Therefore, the function of relieving hypercholesterolemia is achieved.

The invention provides application of farrerol in preparation of a medicine for treating non-alcoholic fatty liver disease. Experimental results show that the farrerol can significantly reduce the liver visceral organ coefficient, the body fat rate, the serum transaminase and the serum total cholesterol level of a non-alcoholic fatty liver model mouse and reduce the accumulation of liver fat and tissue pathological damage, and has a significant protective effect on the non-alcoholic fatty liver of the mouse.

The application discloses a method for simulating a magnetic resonance signal of fatty liver tissue, which comprises the following five steps: obtaining a proton density fat fraction (PDFF) and an effective transverse relaxation rate parameter of the fatty liver tissue; and the method has the beneficial effects that: a three-dimensional simulation model of the fatty liver tissue with different fat fractions is simulated, the PDFF and the predicted value corresponding to the fat fraction are obtained, and thus a correction relationship between the fat fraction and the parameter is established; meanwhile, by adjusting the parameters (magnetic field strength, etc.) in the three-dimensional simulation model of the fatty liver tissue, the influence of fat on the parameter can be corrected in different scenes; and the method can improve the quantification accuracy of liver iron and liver fat through the correlation between the fat fraction and the parameter.

The invention belongs to the technical field of microorganisms, and provides lactobacillus (Ligilbacillus sp.) RG-A helpful for reducing blood fat and application of the lactobacillus (Ligilbacillus sp.) RG-A. The lactobacillus (Ligilbacillus sp.) RG-A is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.33967. The lactobacillus (Ligilbacillus sp.) RG-A has the advantages that the lactobacillus (Ligilbacillus sp. The lactobacillus provided by the invention has good acid resistance and cholate resistance, the survival rate is 74% under the condition of pH 3.0, and the survival rate is 38% under the condition of 0.3% cholate; animal experiments show that the lactobacillus provided by the invention can be applied to preparation of various products for retarding weight gain and improving dyslipidemia and liver fat deposition, and has important clinical application value and industrialization prospect.

The invention relates to an intestinal flora derivative indolepropionic acid capable of relieving obesity and application thereof, and discloses new application of indolepropionic acid in obesity treatment. Indolepropionic acid is prepared through a microbial fermentation method, the purity is higher than that of indolepropionic acid prepared through a chemical synthesis method, multi-target metabolism regulation is achieved by activating a PPAR-gamma signal channel, and the effects of fat metabolism remodeling, liver injury repairing, glycometabolism regulation, inflammation inhibition and the like are achieved; compared with the prior art, the probiotic strain dependence is broken through, a single and definite active component, namely indolepropionic acid, is provided, and the complexity and effect fluctuation of flora intervention are eliminated; the multi-target metabolism regulation is realized, the increase of white fat browning and the reduction of liver fat decomposition are synchronously promoted, and the problem that the fat type cannot be converted by the existing metabolite is solved; the industrial feasibility is optimized, the high-purity indolepropionic acid is prepared through microbial fermentation, the cost is reduced compared with that of a chemical synthesis method, and the purity and production cost bottlenecks are broken through.

The invention relates to the technical field of animal model construction, and discloses a non-alcoholic steatohepatitis model and a construction method and application thereof. The construction method comprises the following steps: performing stable overexpression on an AKT gene in the liver of a mouse by adopting a high-pressure caudal vein transfection technology, and feeding the mouse by adopting a high-fat feed. The non-alcoholic steatohepatitis model constructed by the construction method provided by the invention has the characteristics of liver inflammatory cell infiltration, liver fat deposition, insulin resistance, dyslipidemia and the like, has high clinical pathology similarity with NASH, has a remarkable steatohepatitis phenotype, can be used for researching the occurrence and development mechanism of NASH and evaluating the treatment effect of drugs, and has a wide application prospect. The method is of great significance to prevention and treatment of generation and development of NASH; meanwhile, the construction method is simple to operate, does not need transgenic animals, is short in feeding period, low in cost and high in efficiency, can effectively shorten the establishment period of the non-alcoholic steatohepatitis animal model, and has a good application prospect.

Amino acid compositions and methods to reduce liver fat and circulating concentration of triacylglycerol. The invention further relates to amino acid compositions for recuding liver fat and circulating triacylglycerol in individuals with hepatic steatosis. The composition are parmaceutical or nutritional compositions. The compositions are based on a specially formulated mixture of essential amino acids.

The present invention discloses the preparation of plantain polysaccharide and its application in the preparation of drugs for preventing and treating fatty liver and hemorrhagic syndrome in laying hens, belonging to the field of biomedicine technology. The present invention also provides the application of plantain polysaccharide in the preparation of feed additives for regulating and / or treating fatty liver in laying hens. The present invention comprehensively explores the preventive and therapeutic effects of different doses of plantain polysaccharide on fatty liver in laying hens induced by high-energy and low-protein diets through in vitro and in vivo experimental modeling and detection of relevant indicators, and reduces liver fat deposition by regulating liver fat synthesis and oxidative catabolism and ferroptosis-related signaling pathways, thereby effectively preventing and treating fatty liver and hemorrhagic syndrome in laying hens induced by high-energy and low-protein diets. The present invention also studies the preventive and therapeutic effects of plantain polysaccharide on egg production and fatty liver in laying hens, and concludes that plantain polysaccharide can increase egg production in laying hens and improve production performance.

The invention discloses a traditional Chinese medicine composition and application thereof in medicine for improving non-alcoholic fatty liver, and the traditional Chinese medicine composition comprises pulvis fellis suis, pericarpium citri reticulatae, hawthorn and clostridium butyricum. On one hand, potential targets and pathways of drug diseases are determined in network pharmacological analysis, and on the other hand, in an in-vivo experiment, the drug provided by the invention improves obesity and impaired glucose tolerance caused by HFD, reduces the blood fat level, alleviates inflammation, protects the liver, alleviates liver fat vacuole deposition and fatty degeneration, and has a good application prospect. It is proved that the bile acid-hawthorn and pericarpium citri reticulatae-clostridium butyricum combination has prevention and treatment and protection effects on the HFD-induced non-alcoholic fatty liver disease.

The present invention discloses a long-acting GGG triple-target agonist. The compound of the present invention simultaneously achieves excellent agonist ability at the nM level for the three targets of GLP-1 / GIP / GCGR, and can fully excite the corresponding target organ tissue cells. The compound of the present invention can promote insulin secretion and lower blood sugar; it can also inhibit food intake, delay gastric emptying, increase energy consumption, and ultimately observe a weight loss effect. The compound of the present invention can reduce pancreatic β-cell apoptosis, increase the number of pancreatic β-cells, and improve pancreatic cell function. The compound of the present invention can also improve blood lipids, reduce liver fat accumulation, and inhibit the development of liver inflammation. The compound or composition of the present invention can be used to prevent and / or treat metabolic disorders and related complications. The compound or composition of the present invention can be used to treat bone diseases related to endocrine diseases, metabolic disorders, kidney disease, etc., such as osteoporosis and osteoarthritis.

The application relates to the technical field of medical treatment and discloses a liver chronic disease screening method, a device and a storage medium.The method comprises the following steps: a liver detection system collects liver stiffness data and liver fat attenuation parameters of a target object; a mobile terminal system receives the liver stiffness data and the liver fat attenuation parameters, combines the liver stiffness data and the liver fat attenuation parameters with basic information of a preset target object, generates acquisition characteristic data, carries out label marking matrix processing on pretreatment integrated data of the cloud service system, generates a label marking matrix, carries out fitting residual processing on the label marking matrix, obtains extended decision tree data, carries out discrete sampling processing on the extended decision tree data, obtains a sparse vector, carries out classification calculation processing on the sparse vector, obtains a classification result, and generates a disease screening report based on the classification result.In the embodiment of the application, through system architecture and cloud service system data processing, the early warning timeliness and accuracy of liver chronic disease screening are improved.

The present invention relates to the technical field of microorganisms, in particular to a Lactobacillus acidophilus GOLDGUT-LA100 having functions of lipid lowering, blood glucose lowering and weight loss and application thereof. The Lactobacillus acidophilus GOLDGUT-LA100 provided by the present invention is preserved in China General Microbiological Culture Collection Center, with the preservation number of CGMCC No. 28398. The strain has strong acid resistance, can adapt to the digestive tract environment, and has high bile salt hydrolase activity. At the same time, in animal experiments, the strain significantly reduces blood glucose and serum cholesterol levels, reduces liver fat deposition, reduces adipose tissue inflammation, effectively reduces the weight, and has broad application prospects in the development of products for improving obesity, lowering lipid and lowering blood glucose.

The invention discloses a scatophagus argus liver fat storage cell separation and culture method, and belongs to the technical field of cell biology. According to the present invention, the scatophagus argus liver fat storage cells are obtained through separation by using a perfusion method, and then the scatophagus argus liver fat storage cells obtained through separation are cultured by using a DMEM medium sugar culture medium containing 8-12% of FBS, 4-6% of HBS, 0.005-0.015% of HGF, 0.005-0.015% of HGP, 0.12-0.16 nM of vitamin A acid and 2-2.5 mM of L-glutamine; the ITO cells obtained through separation can be normally cultured to five generations, and the cells have good cell viability.

Disclosed is use of a polypeptide in the preparation of drugs, foods, or health care products for treating obesity and comorbidities thereof, which belongs to the technical field of biological medicines. The polypeptide is a human GPR15L polypeptide or a mouse GPR15L polypeptide and a polypeptide conjugate thereof. The treatment of obesity includes: reducing fat accumulation, promoting fat thermogenesis and catabolism, increasing energy consumption, and reducing body weight. The obesity comorbidities include: chronic inflammation, fatty liver, steatohepatitis, metabolic diseases, cardiovascular and cerebrovascular diseases, osteoarticular diseases, Alzheimer's disease, depression, tumors, and skin diseases. A novel mechanism of action reduces blood glucose and body weight, thereby effectively treating obesity and comorbidities thereof.